Performance of CpG-oligonucleotide DSP30 and interleukin-2 in the cytogenetic study of mature B-cell neoplasms: A systematic review and meta-analysis

IF 5.6 2区医学 Q1 HEMATOLOGY Critical reviews in oncology/hematology Pub Date : 2025-05-01 Epub Date: 2025-02-13 DOI:10.1016/j.critrevonc.2025.104659

Eder Cano-Pérez , Génesis García-Díaz

{"title":"Performance of CpG-oligonucleotide DSP30 and interleukin-2 in the cytogenetic study of mature B-cell neoplasms: A systematic review and meta-analysis","authors":"Eder Cano-Pérez , Génesis García-Díaz","doi":"10.1016/j.critrevonc.2025.104659","DOIUrl":null,"url":null,"abstract":"<div><div>Traditional B-cell mitogens often fail to promote effective cell division in vitro for mature B-cell neoplasms, hindering chromosome analysis. The combination of DSP30 and IL-2 (DSP30/IL-2) has been suggested as a better alternative. This review evaluates DSP30/IL-2 efficiency using a systematic review and meta-analysis of 20 studies. Studies comparing the successful culture rate (SCR) and/or abnormalities detection rate (ADR) of DSP30/IL-2 against traditional mitogens and/or fluorescence in situ hybridization (FISH) were included. Subgroup analyses were performed for cases of chronic lymphocytic leukemia (CCL) and other B-cell neoplasms (OBCN). The findings show no significant difference in SCR between DSP30/IL-2 and traditional mitogens, but DSP30/IL-2 significantly increases ADR. However, DSP30/IL-2's ADR is lower than that of FISH. Analyses by CLL and OBCN subgroups showed similar results. Overall, DSP30/IL-2 is a superior alternative for cytogenetic studies in mature B-cell neoplasms.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"209 ","pages":"Article 104659"},"PeriodicalIF":5.6000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in oncology/hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1040842825000472","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/13 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Traditional B-cell mitogens often fail to promote effective cell division in vitro for mature B-cell neoplasms, hindering chromosome analysis. The combination of DSP30 and IL-2 (DSP30/IL-2) has been suggested as a better alternative. This review evaluates DSP30/IL-2 efficiency using a systematic review and meta-analysis of 20 studies. Studies comparing the successful culture rate (SCR) and/or abnormalities detection rate (ADR) of DSP30/IL-2 against traditional mitogens and/or fluorescence in situ hybridization (FISH) were included. Subgroup analyses were performed for cases of chronic lymphocytic leukemia (CCL) and other B-cell neoplasms (OBCN). The findings show no significant difference in SCR between DSP30/IL-2 and traditional mitogens, but DSP30/IL-2 significantly increases ADR. However, DSP30/IL-2's ADR is lower than that of FISH. Analyses by CLL and OBCN subgroups showed similar results. Overall, DSP30/IL-2 is a superior alternative for cytogenetic studies in mature B-cell neoplasms.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

cpg寡核苷酸DSP30和白细胞介素-2在成熟b细胞肿瘤细胞遗传学研究中的作用：系统回顾和荟萃分析

对于成熟的b细胞肿瘤，传统的b细胞有丝分裂原往往不能促进体外有效的细胞分裂，阻碍了染色体分析。DSP30与IL-2联合应用（DSP30/IL-2）被认为是较好的替代方案。本综述通过对20项研究的系统回顾和荟萃分析来评估DSP30/IL-2的有效性。包括比较DSP30/IL-2对传统丝裂原和/或荧光原位杂交（FISH）的成功培养率（SCR）和/或异常检出率（ADR）的研究。对慢性淋巴细胞白血病（CCL）和其他b细胞肿瘤（OBCN）病例进行亚组分析。结果显示，DSP30/IL-2与传统有丝分裂原的SCR无显著差异，但DSP30/IL-2显著增加ADR。但DSP30/IL-2的不良反应低于FISH。CLL和OBCN亚组分析结果相似。总之，DSP30/IL-2是成熟b细胞肿瘤细胞遗传学研究的一个较好的选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Critical reviews in oncology/hematology 医学-血液学

CiteScore

11.00

自引率

3.20%

发文量

213

审稿时长

55 days

期刊介绍： Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.